Rezultati pretraživanja
  1. is expected to release a review of 2019 performance on 7th Feb, 2020. High accruals in reported earnings predict poor future performance, see: .

  2. prije 3 sata
  3. prije 5 sati

    Short sale volume (not short interest) for at 2020-02-05 is 44%. 52% 39% 45% 30%

  4. prije 5 sati

    Last Chance grabbing >5% Dividend Yield. Raising Dividend almost every Year. I see prices above 100$ soonish.

  5. prije 11 sati

    Sold and due to poor performance. Holding combo

  6. prije 20 sati

    inverted cup and handle? wait and see

  7. prije 21 sat

    sold halve ABBV febr 90 calls at .89 from .27 avg riding remainder

  8. prije 22 sata
  9. prije 24 sata

    RINVOQ™ (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Study in Psoriatic Arthritis

  10. 5. velj

    Make of it what you will, but supposedly anti-HIV drugs made by Gilead , Abbvie and can fight . None of their stocks have benefited.

  11. 4. velj

    These 3 drugs could save the world from 2019-nCOv ; Abbvie’s KALETRA (lopinavir/ ritonavir), Gilead's remdesivir and Regeneron's REGN-EB3. All developed in the USA! KEEP AMERICA GREAT!!! 🇺🇸🇺🇸🇺🇸

  12. 3. velj

    Earnings this week: Monday: . Tuesday and . Wednesday and . Thursday . Friday. will report.

  13. 1. velj
  14. 30. sij

    Buy Abbvie if the stock bounces off the 80 level. Humira sales in Europe appear to be holding up better than anticipated, said Piper Jaffray. This is an opinion, not a recommendation!

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.